The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50 percent reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert Inc.